Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

[Long-term low-molecular-weight heparin therapy during pregnancy: is there a bone risk?].

Khalifa P, Marie-Scemama L.

Therapie. 2013 Jan-Feb;68(1):37-42. doi: 10.2515/therapie/2013008. French.

PMID:
23484659
2.

Minimising the risk of heparin-induced osteoporosis during pregnancy.

Hawkins D, Evans J.

Expert Opin Drug Saf. 2005 May;4(3):583-90. Review.

PMID:
15934862
3.

Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.

Spyropoulos AC, Turpie AG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ; REGIMEN Investigators..

J Thromb Haemost. 2006 Jun;4(6):1246-52.

4.

[Secondary osteoporosis induced by anticoagulants?].

Riess H, Loew A, Himmelreich G.

Orthopade. 2001 Jul;30(7):451-5. German.

PMID:
11515183
6.

Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism.

Wawrzyńska L, Tomkowski WZ, Przedlacki J, Hajduk B, Torbicki A.

Pathophysiol Haemost Thromb. 2003 Mar-Apr;33(2):64-7.

PMID:
14624046
7.

The use of unfractionated heparin and low molecular weight heparins in pregnancy.

Casele HL.

Clin Obstet Gynecol. 2006 Dec;49(4):895-905. Review.

PMID:
17082684
8.

Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity?

Lefkou E, Khamashta M, Hampson G, Hunt BJ.

Lupus. 2010 Jan;19(1):3-12. doi: 10.1177/0961203309353171. Review.

PMID:
19934178
9.

[Placental transfer of low-molecular weight heparin].

Schneider D, Heilmann L, Harenberg J.

Geburtshilfe Frauenheilkd. 1995 Feb;55(2):93-8. German.

PMID:
7758899
10.
11.

Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation?

Schulman S.

Haemostasis. 1998;28 Suppl 3:17-21. Review.

PMID:
10069758
12.

Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.

Kodumuri V, Adigopula S, Singh P, Swaminathan P, Arora R, Khosla S.

Am J Ther. 2011 May;18(3):180-9. doi: 10.1097/MJT.0b013e3181c1218f.

PMID:
20027109
14.

Efficacy and safety of the long-term administration of low-molecular-weight heparins in pregnancy.

Santoro R, Iannaccaro P, Prejanò S, Muleo G.

Blood Coagul Fibrinolysis. 2009 Jun;20(4):240-3. doi: 10.1097/MBC.0b013e3283299c02.

PMID:
19357505
15.

The safety of heparins in end-stage renal disease.

Sonawane S, Kasbekar N, Berns JS.

Semin Dial. 2006 Jul-Aug;19(4):305-10. Review.

PMID:
16893408
16.

Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.

Holzheimer RG.

Eur J Med Res. 2004 Apr 30;9(4):225-39. Review.

PMID:
15210403
17.
18.

[Thrombophilia, preeclampsia and other pregnancy complications].

Vucić N, Frleta M, Petrović D, Ostojić V.

Acta Med Croatica. 2009 Oct;63(4):297-305. Review. Croatian.

PMID:
20034330
19.

The management of thrombosis in pregnancy: role of low-molecular-weight heparin.

Kher A, Bauersachs R, Nielsen JD.

Thromb Haemost. 2007 Apr;97(4):505-13. Review.

PMID:
17393011
20.
Items per page

Supplemental Content

Support Center